Keros Therapeutics, Inc. (KROS) Form 8-K — Jun 25, 2026
$KROSForm 8-KItems 5.02, 7.01, 9.01Filed Jun 25, 2026, 4:02 PM ET0001664710-26-000036Original filing
Keros Therapeutics appointed Anne Prener, M.D., Ph.D., to its board of directors effective July 1, 2026. Dr. Prener will serve as a Class III director with a term expiring at the Company’s 2029 annual meeting of stockholders. Dr.
Key figures
- Annual Cash Retainer
- 41500
- Annual RSUGrant Value
- 75000
- Initial RSUGrant Value
- 150000
- Annual Option Grant Value
- 75000
- Initial Option Grant Value
- 150000
Price after filing
1 day: 0.0%7 days: +8.2%30 days: -2.6%
Close on the filing date to close N calendar days later (from $10.41). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.